IL6 and Non-ST Elevation Myocardial Infarction: The pro-inflammatory cytokine IL-6 was targeted by the specific antibody tocilizumab in the ASSessing the effect of Anti-IL-6 treatment in MI (ASSAIL-MI) trial (296, 297), and the treatment attenuated the inflammatory response and the degree of myocardial damage in patients with non-ST-elevation myocardial infarction.